Intravitreal Steroid for Anterior Ischemic Optic Nerve disease.

Phase 3

• Conditions: on-arteritic Anterior Ischemic Optic Neuropathy; Non-arteritic Anterior Ischemic Optic Neuropathy; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12612000344897
• Lead Sponsor: Khon Kaen University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

acute painless visual loss
- localized optic disc edema
- no associated symptoms (; i.e. headache/scalp tenderness/jaw claudication)
- unilateral involvement with the normal fellow eye
- no previous attack or treatment

Exclusion Criteria

- ocular and/or orbital infection
- other ocular disease that might interfere with visual acuity and/ or the visual field

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BCVA) according to the Snellen chart (converted to logMAR units) at twelfth week[twelfth week];Mean deviation of automated perimetry 30-2 on a Humphrey field analyzer[twelfth week]

Secondary Outcome Measures

Name	Time	Method
Retinal nerve fiber layer thickness using Optical Coherence Tomography (OCT)[twelfth week]